Who Owns Caduet?

Caduet's sustainability and ethics considerations are tied to Pfizer's corporate policies.

Drug Safety and Clinical Evidence: Caduet has been evaluated in multiple clinical trials. The ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial) study demonstrated the benefits of combining blood pressure and cholesterol management in high-risk patients. The FDA continues to monitor adverse event reports for Caduet through its post-marketing surveillance system. Common side effects include peripheral edema, headache, dizziness, and muscle pain. Rare but serious side effects include rhabdomyolysis and liver enzyme elevations.

Access and Affordability: Pfizer offers patient assistance programs for eligible patients who cannot afford their medications. The Pfizer Patient Assistance Program provides free Pfizer medicines to eligible U.S. residents who are uninsured or underinsured. However, branded Caduet remains significantly more expensive than generic alternatives, and most patients are directed to generic versions by their insurers.

Generic Access: The availability of generic amlodipine/atorvastatin has improved access to combination cardiovascular therapy. Generic versions are manufactured by multiple companies, creating competitive pricing that benefits patients and healthcare systems. The generic market for this combination is estimated at approximately $100 to $150 million annually in the United States.

Manufacturing Standards: Pfizer's manufacturing facilities are subject to FDA inspection and must comply with Current Good Manufacturing Practice (cGMP) regulations. The company has received FDA warning letters at some facilities in recent years, though none specifically related to Caduet production. Pfizer publishes an annual sustainability report that includes information on manufacturing quality and compliance.

Environmental Impact: Pharmaceutical manufacturing has environmental impacts including energy consumption, water usage, and chemical waste. Pfizer has committed to carbon neutrality by 2030 for its operations and has set science-based targets for emissions reduction. The company's 2024 sustainability report indicates a 45% reduction in Scope 1 and 2 emissions from a 2019 baseline.

No independent certifications (B Corp, Fair Trade) apply to the Caduet brand.

Caduet does not have a record of independently verified industry awards. The product is a combination of two well-established drugs and has not been recognized as a therapeutic breakthrough by regulatory bodies or professional societies. The clinical value of combining amlodipine and atorvastatin in a single tablet is modest, as both drugs are widely available as separate generics.

This section is omitted in accordance with the brand guide's instruction not to pad with minor or unverifiable accolades.

2008 Caduet Packaging Recall: In 2008, Pfizer recalled specific lots of Caduet tablets due to a packaging issue in which the wrong expiration date was printed on certain bottles. The recall was classified as Class III (unlikely to cause adverse health consequences) by the FDA. No patient harm was reported. Pfizer corrected the labeling issue and resumed distribution.

Lipitor-Related Litigation: While not specific to Caduet, Pfizer has faced litigation related to atorvastatin (Lipitor), one of Caduet's components. In 2013-2014, approximately 1,000 lawsuits were filed alleging that Lipitor caused type 2 diabetes in women. Pfizer won the majority of these cases, with courts ruling that plaintiffs failed to prove that Lipitor caused their diabetes. The FDA updated Lipitor's label in 2012 to include a warning about potential increases in blood sugar levels. This labeling change also applies to Caduet, which contains atorvastatin.

Norvasc-Related Litigation: Pfizer has also faced litigation related to amlodipine (Norvasc), Caduet's other component. In 2008, Pfizer settled a class action lawsuit alleging that Norvasc's patent was improperly maintained, delaying generic entry and keeping prices artificially high. Pfizer paid approximately $78 million to settle the case without admitting wrongdoing. This litigation affected the broader market for amlodipine-containing products, including Caduet.

Patent Disputes: Pfizer's patent for the amlodipine/atorvastatin combination was challenged by generic manufacturers before its 2018 expiration. In 2014, Mylan (now Viatris) filed an abbreviated new drug application (ANDA) seeking to market a generic version of Caduet before the patent expired. Pfizer settled the case, allowing Mylan to launch its generic version in 2018 upon patent expiration. The settlement was reviewed and approved by the FTC.

Off-Label Marketing Concerns: Pfizer has a history of off-label marketing settlements. In 2009, Pfizer paid $2.3 billion to settle Department of Justice allegations that it promoted several drugs, including Lipitor, for off-label uses. This settlement was the largest healthcare fraud settlement in U.S. history at the time. While the settlement did not specifically name Caduet, it covered Pfizer's broader marketing practices during the period when Caduet was being promoted.